Capricor Therapeutics, Inc. (CAPR) 10-Year Financial Performance & Capital Metrics

CAPR • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutCapricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.Show more

Revenue $22M -11.5%
EBITDA -$41M -78.8%
Net Income -$40M -81.6%
EPS (Diluted) -1.15 -38.6%
Gross Margin -124.37% -177.9%
EBITDA Margin -184.73% -102.1%
Operating Margin -191.13% -99.9%
Net Margin -181.71% -105.3%
ROE -48.16% +62.8%
ROIC -43.8% +81.9%
Debt/Equity 0.01 -89.9%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 97 (top 3%)
✓Strong 5Y sales CAGR of 85.8%

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 31.5% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y18.25%

5Y85.83%

3Y349.69%

TTM-52.08%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-140.35%

EPS CAGR

10Y-

5Y-

3Y-

TTM-69.03%

ROCE

10Y Avg-96.25%

5Y Avg-71.36%

3Y Avg-76.86%

Latest-48.12%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	3.78M	3.19M	2.67M	1.67M	1.01M	310.25K	244.9K	2.55M	25.18M	22.27M
Revenue Growth %	-0.09%	-0.16%	-0.16%	-0.37%	-0.4%	-0.69%	-0.21%	9.42%	8.87%	-0.12%
Cost of Goods Sold+	0	0	0	0	5.14M	0	0	21.82M	36.45M	49.97M
COGS % of Revenue	-	-	-	-	5.12%	-	-	8.55%	1.45%	2.24%
Gross Profit+	-8.24M	-12.04M	2.67M	1.67M	-4.14M	310.25K	244.9K	-19.27M	-11.27M	-27.7M
Gross Margin %	-2.18%	-3.78%	1%	1%	-4.12%	1%	1%	-7.55%	-0.45%	-1.24%
Gross Profit Growth %	-1.75%	-0.46%	1.22%	-0.37%	-3.48%	1.07%	-0.21%	-79.67%	0.42%	-1.46%
Operating Expenses+	4.37M	4.93M	4.76M	17M	3.6M	14M	21.18M	10.43M	12.81M	14.87M
OpEx % of Revenue	1.16%	1.55%	1.79%	10.17%	3.58%	45.13%	86.5%	4.09%	0.51%	0.67%
Selling, General & Admin	4.37M	4.93M	4.76M	4.93M	3.6M	5.54M	7.61M	10.43M	12.81M	14.87M
SG&A % of Revenue	1.16%	1.55%	1.79%	2.95%	3.58%	17.87%	31.08%	4.09%	0.51%	0.67%
Research & Development	13.76M	16.04M	10.77M	12.07M	5.14M	8.46M	13.57M	21.82M	36.45M	49.97M
R&D % of Revenue	3.64%	5.03%	4.04%	7.22%	5.12%	27.26%	55.42%	8.55%	1.45%	2.24%
Other Operating Expenses	-1.74M	-809K	-10.77M	0	-5.14M	0	0	-21.82M	-36.45M	-49.97M
Operating Income+	-12.61M	-16.98M	-12.86M	-15.33M	-7.73M	-13.69M	-20.94M	-29.7M	-24.08M	-42.56M
Operating Margin %	-3.34%	-5.32%	-4.82%	-9.17%	-7.7%	-44.13%	-85.5%	-11.64%	-0.96%	-1.91%
Operating Income Growth %	-1.1%	-0.35%	0.24%	-0.19%	0.5%	-0.77%	-0.53%	-0.42%	0.19%	-0.77%
EBITDA+	-12.5M	-16.85M	-12.72M	-15.17M	-7.56M	-13.55M	-20.69M	-29.16M	-23.01M	-41.14M
EBITDA Margin %	-3.31%	-5.28%	-4.77%	-9.08%	-7.52%	-43.66%	-84.5%	-11.43%	-0.91%	-1.85%
EBITDA Growth %	-1.09%	-0.35%	0.25%	-0.19%	0.5%	-0.79%	-0.53%	-0.41%	0.21%	-0.79%
D&A (Non-Cash Add-back)	110.86K	125.72K	144.17K	157.65K	171.96K	143.89K	245.7K	533.13K	1.07M	1.43M
EBIT	-12.61M	-16.98M	2.83M	-15.33M	-7.73M	-13.69M	-20.94M	-29.7M	-24.08M	-42.56M
Net Interest Income+	-248.63K	-344.67K	-398.81K	0	0	0	0	521.53K	1.73M	2.2M
Interest Income	0	0	0	0	0	0	0	521.53K	1.73M	2.2M
Interest Expense	248.63K	344.67K	398.81K	0	0	0	0	0	0	0
Other Income/Expense	-246K	-1.83M	15.29M	135.99K	92.07K	32.94K	915.92K	677.85K	1.79M	2.1M
Pretax Income+	-12.86M	-18.81M	2.43M	-15.19M	-7.64M	-13.66M	-20.02M	-29.02M	-22.29M	-40.47M
Pretax Margin %	-3.4%	-5.9%	0.91%	-9.09%	-7.6%	-44.02%	-81.76%	-11.37%	-0.89%	-1.82%
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-12.86M	-18.81M	2.43M	-15.19M	-7.64M	-13.66M	-20.02M	-29.02M	-22.29M	-40.47M
Net Margin %	-3.4%	-5.9%	0.91%	-9.09%	-7.6%	-44.02%	-81.76%	-11.37%	-0.89%	-1.82%
Net Income Growth %	-1.07%	-0.46%	1.13%	-7.25%	0.5%	-0.79%	-0.47%	-0.45%	0.23%	-0.82%
Net Income (Continuing)	-12.86M	-18.81M	2.43M	-15.19M	-7.64M	-13.66M	-20.02M	-29.02M	-22.29M	-40.47M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-8.09	-10.14	0.90	-5.17	-2.06	-0.88	-0.87	-1.18	-0.83	-1.15
EPS Growth %	-0.52%	-0.25%	1.09%	-6.74%	0.6%	0.57%	0.01%	-0.36%	0.3%	-0.39%
EPS (Basic)	-8.09	-10.14	1.00	-5.17	-2.06	-0.88	-0.87	-1.18	-0.83	-1.15
Diluted Shares Outstanding	1.59M	1.85M	2.68M	2.94M	3.71M	15.57M	23.09M	24.55M	26.78M	35.22M
Basic Shares Outstanding	1.59M	1.85M	2.32M	2.94M	3.71M	15.57M	23.09M	24.55M	26.78M	35.22M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	13.99M	18.11M	15.71M	8.47M	10.54M	33.68M	36.44M	42.89M	50.86M	163.39M
Cash & Short-Term Investments	13.57M	16.19M	14.12M	7.26M	9.89M	32.67M	34.89M	41.42M	39.49M	151.52M
Cash Only	5.57M	3.2M	6.14M	4.26M	3.9M	32.67M	34.89M	9.6M	14.69M	11.29M
Short-Term Investments	8M	12.99M	7.98M	3M	5.99M	0	0	31.82M	24.79M	140.23M
Accounts Receivable	211.94K	223.34K	344.57K	204.87K	87.97K	56K	391.75K	547.58K	10.37M	10.37M
Days Sales Outstanding	20.49	25.55	47.18	44.75	31.95	65.88	583.87	78.33	150.36	169.93
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	1.35M	742K	285.83K	0	-56K	0	919.89K	0	0
Total Non-Current Assets+	2.08M	639.01K	561.11K	775.77K	568.91K	941.71K	4.89M	7.21M	7.88M	7.1M
Property, Plant & Equipment	318.57K	435.34K	372.1K	574.21K	442.81K	850.85K	4.62M	6.94M	7.61M	6.87M
Fixed Asset Turnover	11.85x	7.33x	7.16x	2.91x	2.27x	0.36x	0.05x	0.37x	3.31x	3.24x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	1.69M	142.25K	93.05K	204.87K	6.5K	2.17K	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	70.15K	61.43K	95.97K	151.79K	119.61K	88.7K	275.72K	268.17K	268.17K	221.7K
Total Assets+	16.07M	18.75M	16.27M	9.25M	11.11M	34.62M	41.33M	50.09M	58.73M	170.48M
Asset Turnover	0.23x	0.17x	0.16x	0.18x	0.09x	0.01x	0.01x	0.05x	0.43x	0.13x
Asset Growth %	0.18%	0.17%	-0.13%	-0.43%	0.2%	2.11%	0.19%	0.21%	0.17%	1.9%
Total Current Liabilities+	6.53M	4.9M	1.67M	1.26M	897.99K	2.97M	4.13M	23.59M	31.27M	21.03M
Accounts Payable	2.53M	3.04M	1.67M	1.26M	897.99K	2.72M	0	4.83M	6.24M	8.18M
Days Payables Outstanding	-	-	-	-	63.75	-	-	80.88	62.49	59.76
Short-Term Debt	0	0	0	0	0	246.69K	0	0	0	0
Deferred Revenue (Current)	1000K	1000K	0	0	0	0	0	1000K	0	0
Other Current Liabilities	0	0	0	0	0	0	3.72M	0	24.27M	12M
Current Ratio	2.14x	3.70x	9.40x	6.75x	11.74x	11.33x	8.82x	1.82x	1.63x	7.77x
Quick Ratio	2.14x	3.70x	9.40x	6.75x	11.74x	11.33x	8.82x	1.82x	1.63x	7.77x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	10.57M	17.86M	3.38M	3.38M	3.38M	3.45M	5.83M	14.72M	4.86M	3.99M
Long-Term Debt	9.16M	13.91M	0	0	0	71.47K	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	2.45M	1.88M	1.49M	616.32K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	505.36K	3.95M	3.38M	3.38M	3.38M	3.38M	3.38M	3.38M	3.38M	3.38M
Total Liabilities	17.1M	22.75M	5.05M	4.63M	4.27M	6.42M	9.96M	38.31M	36.13M	25.02M
Total Debt+	9.16M	13.91M	0	0	0	318.16K	2.87M	2.56M	2.24M	1.45M
Net Debt	3.59M	10.7M	-6.14M	-4.26M	-3.9M	-32.35M	-32.01M	-7.04M	-12.46M	-9.84M
Debt / Equity	-	-	-	-	-	0.01x	0.09x	0.22x	0.10x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-50.73x	-49.26x	-32.25x	-	-	-	-	-	-	-
Total Equity+	-1.03M	-4M	11.23M	4.62M	6.84M	28.2M	31.37M	11.79M	22.6M	145.46M
Equity Growth %	0.83%	-2.88%	3.8%	-0.59%	0.48%	3.12%	0.11%	-0.62%	0.92%	5.44%
Book Value per Share	-0.65	-2.16	4.19	1.57	1.84	1.81	1.36	0.48	0.84	4.13
Total Shareholders' Equity	-1.03M	-4M	11.23M	4.62M	6.84M	28.2M	31.37M	11.79M	22.6M	145.46M
Common Stock	16.25K	21.4K	26.27K	3.14K	5.23K	20.58K	24.18K	25.24K	31.15K	45.58K
Retained Earnings	-35.17M	-53.98M	-51.55M	-66.74M	-74.38M	-88.04M	-108.06M	-137.08M	-159.37M	-199.83M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	9.38K	3.52K	11.62K	12.39K	-757	0	0	105.24K	235.81K	1.03M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-10.82M	-15.8M	-14.23M	-13.86M	-6.82M	-10.05M	-16.81M	4.92M	-25.6M	-40M
Operating CF Margin %	-2.86%	-4.95%	-5.34%	-8.3%	-6.79%	-32.41%	-68.64%	1.93%	-1.02%	-1.8%
Operating CF Growth %	-12.28%	-0.46%	0.1%	0.03%	0.51%	-0.47%	-0.67%	1.29%	-6.21%	-0.56%
Net Income	-12.86M	-18.81M	2.43M	-15.19M	-7.64M	-13.66M	-20.02M	-29.02M	-22.29M	-40.47M
Depreciation & Amortization	110.86K	125.72K	144.17K	157.65K	171.96K	143.89K	245.7K	533.13K	1.07M	1.43M
Stock-Based Compensation	1.57M	1.96M	1.71M	1.73M	700.98K	1.95M	2.97M	4.46M	7.39M	9.77M
Deferred Taxes	-1.57M	-1.96M	0	0	0	-325.89K	-310.25K	0	0	0
Other Non-Cash Items	1.57M	3.46M	-15.65M	2.32M	2.72K	325.89K	129.73K	196.01K	-18.24K	65.54K
Working Capital Changes	355.96K	-583.03K	-2.86M	-554.59K	-55.34K	1.51M	182.34K	28.75M	-11.75M	-10.78M
Change in Receivables	148.29M	-11.4M	-121.24M	139.71M	116.9M	87.97M	-391.75M	-155.83K	-9.82M	3.5K
Change in Inventory	-147.88M	11.6M	121.36M	-139.79M	156.28M	-1.91B	391.75M	0	0	0
Change in Payables	749.87K	645.16K	-1.86M	-415.46K	-273.18M	1.83B	991.17K	1.21M	1.33M	1.94M
Cash from Investing+	-8.14M	-5.19M	4.98M	4.67M	-3M	5.44M	-1.2M	-35.07M	5.11M	-116.18M
Capital Expenditures	-151.23K	-193.74K	-32.19K	-316.49K	0	-547.6K	-1.2M	-3.36M	-2.05M	-1.54M
CapEx % of Revenue	0.04%	0.06%	0.01%	0.19%	-	1.77%	4.88%	1.32%	0.08%	0.07%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-21.53M	-1.77M	5.01M	4.99M	0	5.99M	0	0	0	0
Cash from Financing+	16.49M	18.63M	11.58M	6.85M	9.18M	33.38M	20.23M	4.87M	25.58M	152.77M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	45.46K	13.97K	6.64K	139.14K	3.22K	5.72M	50.56K	70.3K	64.6K	450.17K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-10.97M	-16M	-14.26M	-14.18M	-6.82M	-10.6M	-18.01M	1.56M	-27.64M	-41.53M
FCF Margin %	-2.9%	-5.01%	-5.35%	-8.49%	-6.79%	-34.17%	-73.52%	0.61%	-1.1%	-1.87%
FCF Growth %	-15.21%	-0.46%	0.11%	0.01%	0.52%	-0.55%	-0.7%	1.09%	-18.76%	-0.5%
FCF per Share	-6.90	-8.62	-5.32	-4.82	-1.84	-0.68	-0.78	0.06	-1.03	-1.18
FCF Conversion (FCF/Net Income)	0.84x	0.84x	-5.85x	0.91x	0.89x	0.74x	0.84x	-0.17x	1.15x	0.99x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	67.31%	-191.78%	-133.42%	-77.95%	-67.23%	-134.49%	-129.63%	-48.16%
Return on Invested Capital (ROIC)	-	-275.18%	-163.71%	-422.38%	-351.93%	-	-	-1087.55%	-242.63%	-43.8%
Gross Margin	-218.22%	-377.52%	100%	100%	-411.61%	100%	100%	-755.07%	-44.76%	-124.37%
Net Margin	-340.49%	-589.56%	91.19%	-909.1%	-760.36%	-4401.94%	-8175.86%	-1137.37%	-88.52%	-181.71%
Debt / Equity	-	-	-	-	-	0.01x	0.09x	0.22x	0.10x	0.01x
Interest Coverage	-50.73x	-49.26x	-32.25x	-	-	-	-	-	-	-
FCF Conversion	0.84x	0.84x	-5.85x	0.91x	0.89x	0.74x	0.84x	-0.17x	1.15x	0.99x
Revenue Growth	-9.38%	-15.52%	-16.43%	-37.32%	-39.85%	-69.13%	-21.06%	941.85%	886.81%	-11.55%

Frequently Asked Questions

Growth & Financials

Capricor Therapeutics, Inc. (CAPR) reported $11.1M in revenue for fiscal year 2024. This represents a 721% increase from $1.4M in 2011.

Capricor Therapeutics, Inc. (CAPR) saw revenue decline by 11.5% over the past year.

Capricor Therapeutics, Inc. (CAPR) reported a net loss of $82.0M for fiscal year 2024.

Dividend & Returns

Capricor Therapeutics, Inc. (CAPR) has a return on equity (ROE) of -48.2%. Negative ROE indicates the company is unprofitable.

Capricor Therapeutics, Inc. (CAPR) had negative free cash flow of $44.7M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Capricor Therapeutics, Inc. (CAPR) 10-Year Financial Performance & Capital Metrics

CAPR • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

Revenue $22M -11.5%
EBITDA -$41M -78.8%
Net Income -$40M -81.6%
EPS (Diluted) -1.15 -38.6%
Gross Margin -124.37% -177.9%
EBITDA Margin -184.73% -102.1%
Operating Margin -191.13% -99.9%
Net Margin -181.71% -105.3%
ROE -48.16% +62.8%
ROIC -43.8% +81.9%
Debt/Equity 0.01 -89.9%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 97 (top 3%)
✓Strong 5Y sales CAGR of 85.8%

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 31.5% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y18.25%

5Y85.83%

3Y349.69%

TTM-52.08%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-140.35%

EPS CAGR

10Y-

5Y-

3Y-

TTM-69.03%

ROCE

10Y Avg-96.25%

5Y Avg-71.36%

3Y Avg-76.86%

Latest-48.12%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	3.78M	3.19M	2.67M	1.67M	1.01M	310.25K	244.9K	2.55M	25.18M	22.27M
Revenue Growth %	-0.09%	-0.16%	-0.16%	-0.37%	-0.4%	-0.69%	-0.21%	9.42%	8.87%	-0.12%
Cost of Goods Sold+	0	0	0	0	5.14M	0	0	21.82M	36.45M	49.97M
COGS % of Revenue	-	-	-	-	5.12%	-	-	8.55%	1.45%	2.24%
Gross Profit+	-8.24M	-12.04M	2.67M	1.67M	-4.14M	310.25K	244.9K	-19.27M	-11.27M	-27.7M
Gross Margin %	-2.18%	-3.78%	1%	1%	-4.12%	1%	1%	-7.55%	-0.45%	-1.24%
Gross Profit Growth %	-1.75%	-0.46%	1.22%	-0.37%	-3.48%	1.07%	-0.21%	-79.67%	0.42%	-1.46%
Operating Expenses+	4.37M	4.93M	4.76M	17M	3.6M	14M	21.18M	10.43M	12.81M	14.87M
OpEx % of Revenue	1.16%	1.55%	1.79%	10.17%	3.58%	45.13%	86.5%	4.09%	0.51%	0.67%
Selling, General & Admin	4.37M	4.93M	4.76M	4.93M	3.6M	5.54M	7.61M	10.43M	12.81M	14.87M
SG&A % of Revenue	1.16%	1.55%	1.79%	2.95%	3.58%	17.87%	31.08%	4.09%	0.51%	0.67%
Research & Development	13.76M	16.04M	10.77M	12.07M	5.14M	8.46M	13.57M	21.82M	36.45M	49.97M
R&D % of Revenue	3.64%	5.03%	4.04%	7.22%	5.12%	27.26%	55.42%	8.55%	1.45%	2.24%
Other Operating Expenses	-1.74M	-809K	-10.77M	0	-5.14M	0	0	-21.82M	-36.45M	-49.97M
Operating Income+	-12.61M	-16.98M	-12.86M	-15.33M	-7.73M	-13.69M	-20.94M	-29.7M	-24.08M	-42.56M
Operating Margin %	-3.34%	-5.32%	-4.82%	-9.17%	-7.7%	-44.13%	-85.5%	-11.64%	-0.96%	-1.91%
Operating Income Growth %	-1.1%	-0.35%	0.24%	-0.19%	0.5%	-0.77%	-0.53%	-0.42%	0.19%	-0.77%
EBITDA+	-12.5M	-16.85M	-12.72M	-15.17M	-7.56M	-13.55M	-20.69M	-29.16M	-23.01M	-41.14M
EBITDA Margin %	-3.31%	-5.28%	-4.77%	-9.08%	-7.52%	-43.66%	-84.5%	-11.43%	-0.91%	-1.85%
EBITDA Growth %	-1.09%	-0.35%	0.25%	-0.19%	0.5%	-0.79%	-0.53%	-0.41%	0.21%	-0.79%
D&A (Non-Cash Add-back)	110.86K	125.72K	144.17K	157.65K	171.96K	143.89K	245.7K	533.13K	1.07M	1.43M
EBIT	-12.61M	-16.98M	2.83M	-15.33M	-7.73M	-13.69M	-20.94M	-29.7M	-24.08M	-42.56M
Net Interest Income+	-248.63K	-344.67K	-398.81K	0	0	0	0	521.53K	1.73M	2.2M
Interest Income	0	0	0	0	0	0	0	521.53K	1.73M	2.2M
Interest Expense	248.63K	344.67K	398.81K	0	0	0	0	0	0	0
Other Income/Expense	-246K	-1.83M	15.29M	135.99K	92.07K	32.94K	915.92K	677.85K	1.79M	2.1M
Pretax Income+	-12.86M	-18.81M	2.43M	-15.19M	-7.64M	-13.66M	-20.02M	-29.02M	-22.29M	-40.47M
Pretax Margin %	-3.4%	-5.9%	0.91%	-9.09%	-7.6%	-44.02%	-81.76%	-11.37%	-0.89%	-1.82%
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-12.86M	-18.81M	2.43M	-15.19M	-7.64M	-13.66M	-20.02M	-29.02M	-22.29M	-40.47M
Net Margin %	-3.4%	-5.9%	0.91%	-9.09%	-7.6%	-44.02%	-81.76%	-11.37%	-0.89%	-1.82%
Net Income Growth %	-1.07%	-0.46%	1.13%	-7.25%	0.5%	-0.79%	-0.47%	-0.45%	0.23%	-0.82%
Net Income (Continuing)	-12.86M	-18.81M	2.43M	-15.19M	-7.64M	-13.66M	-20.02M	-29.02M	-22.29M	-40.47M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-8.09	-10.14	0.90	-5.17	-2.06	-0.88	-0.87	-1.18	-0.83	-1.15
EPS Growth %	-0.52%	-0.25%	1.09%	-6.74%	0.6%	0.57%	0.01%	-0.36%	0.3%	-0.39%
EPS (Basic)	-8.09	-10.14	1.00	-5.17	-2.06	-0.88	-0.87	-1.18	-0.83	-1.15
Diluted Shares Outstanding	1.59M	1.85M	2.68M	2.94M	3.71M	15.57M	23.09M	24.55M	26.78M	35.22M
Basic Shares Outstanding	1.59M	1.85M	2.32M	2.94M	3.71M	15.57M	23.09M	24.55M	26.78M	35.22M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	13.99M	18.11M	15.71M	8.47M	10.54M	33.68M	36.44M	42.89M	50.86M	163.39M
Cash & Short-Term Investments	13.57M	16.19M	14.12M	7.26M	9.89M	32.67M	34.89M	41.42M	39.49M	151.52M
Cash Only	5.57M	3.2M	6.14M	4.26M	3.9M	32.67M	34.89M	9.6M	14.69M	11.29M
Short-Term Investments	8M	12.99M	7.98M	3M	5.99M	0	0	31.82M	24.79M	140.23M
Accounts Receivable	211.94K	223.34K	344.57K	204.87K	87.97K	56K	391.75K	547.58K	10.37M	10.37M
Days Sales Outstanding	20.49	25.55	47.18	44.75	31.95	65.88	583.87	78.33	150.36	169.93
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	1.35M	742K	285.83K	0	-56K	0	919.89K	0	0
Total Non-Current Assets+	2.08M	639.01K	561.11K	775.77K	568.91K	941.71K	4.89M	7.21M	7.88M	7.1M
Property, Plant & Equipment	318.57K	435.34K	372.1K	574.21K	442.81K	850.85K	4.62M	6.94M	7.61M	6.87M
Fixed Asset Turnover	11.85x	7.33x	7.16x	2.91x	2.27x	0.36x	0.05x	0.37x	3.31x	3.24x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	1.69M	142.25K	93.05K	204.87K	6.5K	2.17K	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	70.15K	61.43K	95.97K	151.79K	119.61K	88.7K	275.72K	268.17K	268.17K	221.7K
Total Assets+	16.07M	18.75M	16.27M	9.25M	11.11M	34.62M	41.33M	50.09M	58.73M	170.48M
Asset Turnover	0.23x	0.17x	0.16x	0.18x	0.09x	0.01x	0.01x	0.05x	0.43x	0.13x
Asset Growth %	0.18%	0.17%	-0.13%	-0.43%	0.2%	2.11%	0.19%	0.21%	0.17%	1.9%
Total Current Liabilities+	6.53M	4.9M	1.67M	1.26M	897.99K	2.97M	4.13M	23.59M	31.27M	21.03M
Accounts Payable	2.53M	3.04M	1.67M	1.26M	897.99K	2.72M	0	4.83M	6.24M	8.18M
Days Payables Outstanding	-	-	-	-	63.75	-	-	80.88	62.49	59.76
Short-Term Debt	0	0	0	0	0	246.69K	0	0	0	0
Deferred Revenue (Current)	1000K	1000K	0	0	0	0	0	1000K	0	0
Other Current Liabilities	0	0	0	0	0	0	3.72M	0	24.27M	12M
Current Ratio	2.14x	3.70x	9.40x	6.75x	11.74x	11.33x	8.82x	1.82x	1.63x	7.77x
Quick Ratio	2.14x	3.70x	9.40x	6.75x	11.74x	11.33x	8.82x	1.82x	1.63x	7.77x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	10.57M	17.86M	3.38M	3.38M	3.38M	3.45M	5.83M	14.72M	4.86M	3.99M
Long-Term Debt	9.16M	13.91M	0	0	0	71.47K	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	2.45M	1.88M	1.49M	616.32K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	505.36K	3.95M	3.38M	3.38M	3.38M	3.38M	3.38M	3.38M	3.38M	3.38M
Total Liabilities	17.1M	22.75M	5.05M	4.63M	4.27M	6.42M	9.96M	38.31M	36.13M	25.02M
Total Debt+	9.16M	13.91M	0	0	0	318.16K	2.87M	2.56M	2.24M	1.45M
Net Debt	3.59M	10.7M	-6.14M	-4.26M	-3.9M	-32.35M	-32.01M	-7.04M	-12.46M	-9.84M
Debt / Equity	-	-	-	-	-	0.01x	0.09x	0.22x	0.10x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-50.73x	-49.26x	-32.25x	-	-	-	-	-	-	-
Total Equity+	-1.03M	-4M	11.23M	4.62M	6.84M	28.2M	31.37M	11.79M	22.6M	145.46M
Equity Growth %	0.83%	-2.88%	3.8%	-0.59%	0.48%	3.12%	0.11%	-0.62%	0.92%	5.44%
Book Value per Share	-0.65	-2.16	4.19	1.57	1.84	1.81	1.36	0.48	0.84	4.13
Total Shareholders' Equity	-1.03M	-4M	11.23M	4.62M	6.84M	28.2M	31.37M	11.79M	22.6M	145.46M
Common Stock	16.25K	21.4K	26.27K	3.14K	5.23K	20.58K	24.18K	25.24K	31.15K	45.58K
Retained Earnings	-35.17M	-53.98M	-51.55M	-66.74M	-74.38M	-88.04M	-108.06M	-137.08M	-159.37M	-199.83M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	9.38K	3.52K	11.62K	12.39K	-757	0	0	105.24K	235.81K	1.03M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-10.82M	-15.8M	-14.23M	-13.86M	-6.82M	-10.05M	-16.81M	4.92M	-25.6M	-40M
Operating CF Margin %	-2.86%	-4.95%	-5.34%	-8.3%	-6.79%	-32.41%	-68.64%	1.93%	-1.02%	-1.8%
Operating CF Growth %	-12.28%	-0.46%	0.1%	0.03%	0.51%	-0.47%	-0.67%	1.29%	-6.21%	-0.56%
Net Income	-12.86M	-18.81M	2.43M	-15.19M	-7.64M	-13.66M	-20.02M	-29.02M	-22.29M	-40.47M
Depreciation & Amortization	110.86K	125.72K	144.17K	157.65K	171.96K	143.89K	245.7K	533.13K	1.07M	1.43M
Stock-Based Compensation	1.57M	1.96M	1.71M	1.73M	700.98K	1.95M	2.97M	4.46M	7.39M	9.77M
Deferred Taxes	-1.57M	-1.96M	0	0	0	-325.89K	-310.25K	0	0	0
Other Non-Cash Items	1.57M	3.46M	-15.65M	2.32M	2.72K	325.89K	129.73K	196.01K	-18.24K	65.54K
Working Capital Changes	355.96K	-583.03K	-2.86M	-554.59K	-55.34K	1.51M	182.34K	28.75M	-11.75M	-10.78M
Change in Receivables	148.29M	-11.4M	-121.24M	139.71M	116.9M	87.97M	-391.75M	-155.83K	-9.82M	3.5K
Change in Inventory	-147.88M	11.6M	121.36M	-139.79M	156.28M	-1.91B	391.75M	0	0	0
Change in Payables	749.87K	645.16K	-1.86M	-415.46K	-273.18M	1.83B	991.17K	1.21M	1.33M	1.94M
Cash from Investing+	-8.14M	-5.19M	4.98M	4.67M	-3M	5.44M	-1.2M	-35.07M	5.11M	-116.18M
Capital Expenditures	-151.23K	-193.74K	-32.19K	-316.49K	0	-547.6K	-1.2M	-3.36M	-2.05M	-1.54M
CapEx % of Revenue	0.04%	0.06%	0.01%	0.19%	-	1.77%	4.88%	1.32%	0.08%	0.07%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-21.53M	-1.77M	5.01M	4.99M	0	5.99M	0	0	0	0
Cash from Financing+	16.49M	18.63M	11.58M	6.85M	9.18M	33.38M	20.23M	4.87M	25.58M	152.77M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	45.46K	13.97K	6.64K	139.14K	3.22K	5.72M	50.56K	70.3K	64.6K	450.17K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-10.97M	-16M	-14.26M	-14.18M	-6.82M	-10.6M	-18.01M	1.56M	-27.64M	-41.53M
FCF Margin %	-2.9%	-5.01%	-5.35%	-8.49%	-6.79%	-34.17%	-73.52%	0.61%	-1.1%	-1.87%
FCF Growth %	-15.21%	-0.46%	0.11%	0.01%	0.52%	-0.55%	-0.7%	1.09%	-18.76%	-0.5%
FCF per Share	-6.90	-8.62	-5.32	-4.82	-1.84	-0.68	-0.78	0.06	-1.03	-1.18
FCF Conversion (FCF/Net Income)	0.84x	0.84x	-5.85x	0.91x	0.89x	0.74x	0.84x	-0.17x	1.15x	0.99x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	67.31%	-191.78%	-133.42%	-77.95%	-67.23%	-134.49%	-129.63%	-48.16%
Return on Invested Capital (ROIC)	-	-275.18%	-163.71%	-422.38%	-351.93%	-	-	-1087.55%	-242.63%	-43.8%
Gross Margin	-218.22%	-377.52%	100%	100%	-411.61%	100%	100%	-755.07%	-44.76%	-124.37%
Net Margin	-340.49%	-589.56%	91.19%	-909.1%	-760.36%	-4401.94%	-8175.86%	-1137.37%	-88.52%	-181.71%
Debt / Equity	-	-	-	-	-	0.01x	0.09x	0.22x	0.10x	0.01x
Interest Coverage	-50.73x	-49.26x	-32.25x	-	-	-	-	-	-	-
FCF Conversion	0.84x	0.84x	-5.85x	0.91x	0.89x	0.74x	0.84x	-0.17x	1.15x	0.99x
Revenue Growth	-9.38%	-15.52%	-16.43%	-37.32%	-39.85%	-69.13%	-21.06%	941.85%	886.81%	-11.55%

Frequently Asked Questions

Growth & Financials

Capricor Therapeutics, Inc. (CAPR) reported $11.1M in revenue for fiscal year 2024. This represents a 721% increase from $1.4M in 2011.

Capricor Therapeutics, Inc. (CAPR) saw revenue decline by 11.5% over the past year.

Capricor Therapeutics, Inc. (CAPR) reported a net loss of $82.0M for fiscal year 2024.

Dividend & Returns

Capricor Therapeutics, Inc. (CAPR) has a return on equity (ROE) of -48.2%. Negative ROE indicates the company is unprofitable.

Capricor Therapeutics, Inc. (CAPR) had negative free cash flow of $44.7M in fiscal year 2024, likely due to heavy capital investments.